Evidence map›Paper›PMID 39966805›Full record

ArticleCancer cell international2025

Potential value of immunogenic cell death related-genes in refining European leukemiaNet guidelines classification and predicting the immune infiltration landscape in acute myeloid leukemia.

Changqing Jiao, Xiaoyu Ma, Jianling Cui, Bobin Su, Fei Xu, Enbo Chen, Junjie Zhou, Jifei Dai, Mengya Pan, Zhangbiao Long and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Changqing JiaoDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Xiaoyu MaDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jianling CuiDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Bobin SuDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Fei XuDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Enbo ChenDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Junjie ZhouDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jifei DaiDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Mengya PanDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Zhangbiao LongDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jian GeDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. gejian@ahmu.edu.cn.

Funding

Clinical Trial Initiative Projects of The First Affiliated Hospital of Anhui Medical University LCYJ2021YB009Key Research and development Project of Anhui Province 201904a07020057National Natural Science Foundation of China 82370175Postgraduate Innovation Research and Practice Program of Anhui Medical University YJS20230016Research Foundation of Anhui Institute of Translational Medicine 2021zhyx-C32Research Foundation of Anhui Medical University 2020xkj166
6 · The paper itself

Abstract

Immunogenic cell death (ICD) is the kind of cell death that triggers the immune system. It affects several tumors, whereas its significance for prognosis in acute myeloid leukemia (AML) remains uncertain. AML categorization by cytogenetic variables is inaccurate. In addition, risk stratification of AML based on cytogenetics is imprecise. The data of AML patients were extracted from 4 databases, a total of 1,537 patients. Univariate and LASSO Cox regression analyses were conducted to construct an ICD risk signature (ICDRS). The ICDRS showed strong prognostic value for AML through Kaplan-Meier, Cox, ROC analyses and nomogram. Combining the ICDRS with the European LeukemiaNet (ELN) classification to redefine the risk stratification can better predict the prognosis of AML. Moreover, the ICDRS was examined to identify gene functional enrichment, immunological characteristics, drug susceptibility, and somatic mutation, which revealed considerable variations among different risk categories. We further validated the expression of ICDRS in the AML bone marrow microenvironment by single-cell RNA (scRNA) analysis. Ultimately, the functional role of CASP1 was proven in AML by a series of in-vitro experiments. Our study highlights the significant impact of ICDRS on AML, which may improve ELN risk classification, predict immune landscapes, and guide personalized therapy.

Indexed as

Acute myeloid leukemiaEuropean leukemiaNetImmuneImmunogenic cell deathPrognosisSignature

Identifiers

PMID39966805
PMCPMC11837611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.